Navigation Links
Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
Date:1/26/2009

Novel Fluoroquinolone Demonstrates Safety and Efficacy in Treatment of Skin Infections

NEW HAVEN, Conn., Jan. 26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, today announced positive final results from a Phase 2 clinical trial of its novel fluoroquinolone antibiotic, delafloxacin (RX-3341), in the treatment of complicated skin and skin structure infections (cSSSI).

Separately, Rib-X today also announced that the company closed on a $25 million financing, which will fund the ongoing development of its pipeline of novel antibiotics. This round included participation from all of Rib-X's major investors, including: Warburg Pincus, ABS Ventures, Axiom Ventures, EuclidSR Partners, MedImmune Ventures, Oxford Bioscience Partners, S.R. One, and Vox Equity Partners I.

In the double-blind study, delafloxacin was administered intravenously at two different doses, 300 mg twice daily (BID) and 450 mg BID; the comparator was tigecycline (TYGACIL(R), Wyeth Pharmaceuticals), the only broad spectrum agent recently approved (2005) by the FDA for use in cSSSI. Delafloxacin showed comparable efficacy and improved tolerability relative to tigecycline at the FDA-approved dosing regimen for this indication. In the clinically evaluable population, the cure rates for delafloxacin 300 mg BID and 450 mg BID were 97.2% and 92.5%, respectively, while the cure rate for tigecycline was 91.2%.

Staphylococcus aureus was the most frequently isolated pathogen, accounting for approximately 85% of all pathogens collected. Approximately 70% (68/96) of the S. aureus isolates were methicillin-resistant (MRSA) and 63% of the MRSA were levofloxacin resistant. MIC90 values for delafloxacin, tigecycline, and levofloxacin against all S. aureus'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rib-X Pharmaceuticals to Present at the 2008 ICAAC/IDSA Joint Meeting
2. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
3. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
4. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
5. MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine
6. Axikin Pharmaceuticals Spins out of Actimis
7. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
8. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
9. Cumberland Pharmaceuticals Appoints Lee Product Director
10. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
11. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... FREMONT, Calif. , Oct. 30, 2014 /PRNewswire/ ... clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and ... third quarter 2014 financial results on Thursday, November ... team will host a live conference call and ... financial results and provide a business update. ...
(Date:10/30/2014)... 2014 Deep Research Report on Global ... and in-depth research report on the China Naltrexone ... including its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... macroeconomic environment & economic situation analysis. The report ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 ... collaboration provider, offers Office 365 end users the ... a complete phone system by adding voice enablement ... (O365) includes Lync Online, a communication tool that ... calls. With hosted voice, O365 becomes a comprehensive ...
(Date:10/30/2014)... October 30, 2014 James Sherley says he ... adult tissue stem cell technology since his days as a ... Philadelphia in the late 1990’s. Sherley founded the ASCTC ... company holds all the intellectual property developed in Sherley’s research ... the Massachusetts Institute of Technology (MIT), and more recently as ...
Breaking Biology Technology:Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 3SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4
... 30 ChemRisk, a leading scientific,consulting firm, was ... examine,the recent publication by Institute for Agriculture and ... High Fructose Corn Syrup," and the,Environmental Health journal ... product sugar," by Dufault et al, 2009, and ...
... risk factors better than standard cholesterol test and traditional ... Traditional risk factors such as age, standard cholesterol ... predicting heart disease risk in younger, healthy adults with ... to a recent study published in Clinical Cardiology ...
... Mass., Jan. 30 Jeff Olson, Manager of Nucleic ... Enrichment of Genomic Loci for Targeted Sequencing Applications ... RainStorm micro-droplet technology on the new RDT 1000 instrument, ... (AGBT) conference on Friday, February 6th, in Marco Island, ...
Cached Biology Technology:Recent Reports Regarding Mercury and High Fructose Corn Syrup Flawed and Misleading 2Recent Reports Regarding Mercury and High Fructose Corn Syrup Flawed and Misleading 3Recent Reports Regarding Mercury and High Fructose Corn Syrup Flawed and Misleading 4Traditional Risk Factors Often Miss Heart Disease Warning Signs 2Traditional Risk Factors Often Miss Heart Disease Warning Signs 3Traditional Risk Factors Often Miss Heart Disease Warning Signs 4'Enrichment of Genomic Loci for Targeted Sequencing Application' Is Focus of 2009 AGBT Conference Workshop 2'Enrichment of Genomic Loci for Targeted Sequencing Application' Is Focus of 2009 AGBT Conference Workshop 3
(Date:10/29/2014)... rage. Thousands of scientists worldwide are conducting research on ... nanoparticles from sun creams can get through the skin ... products are as hazardous for the lungs as asbestos ... get into the blood via the intestinal flora, for ... – and the number of scientific projects is skyrocketing: ...
(Date:10/29/2014)... to as ,facultative, form part—together with other cells—of tissues ... cells from the others. However, they have a very ... stem cells again. This phenomenon is something that happens ... stimulate tissue growth, thus allowing the regeneration of the ... the underlying mechanism that allows these cells to ...
(Date:10/29/2014)... – Ghrelin is a hormone released by the stomach ... commonly viewed as a psychoactive substance that primarily affects ... food. , This knowledge, combined with findings from ... has the potential to stimulate alcohol craving. , Dr. ... and found that, as they had anticipated, alcohol craving ...
Breaking Biology News(10 mins):Nanosafety research: The quest for the gold standard 2Nanosafety research: The quest for the gold standard 3A mechanism that allows a differentiated cell to reactivate as a stem cell revealed 2Ghrelin stimulates an appetite for drinking alcohol 2
... VEGAS , Jan. 7, 2014 from ShowStoppers @ ... of securing consumer data on mobile and other digital devices, ... data once it leaves the device and enters the cloud. ... announced the formalization of its Biometric Open Standards Protocols (BOPS). ...
... This news release is available in Portuguese . ... is available in Portuguese . , ... goes beyond the presence or absence of wings. In a study published ... Keller and Patrcia Beldade from the Instituto Gulbenkian de Cincia (IGC, ...
... underrepresented among speakers at scientific meetings, both in absolute ... a new study suggests one way to address this ... published in mBio , the online open-access journal ... inclusion of at least one woman on a convening ...
Cached Biology News:Hoyos Labs Issues Biometric Open Protocol Standard for Safer Authentication 2Hoyos Labs Issues Biometric Open Protocol Standard for Safer Authentication 3Ants shape their thoraces to match the tasks they perform 2Ants shape their thoraces to match the tasks they perform 3Including women on convening committees increases women speakers at scientific meetings 2
Troponin I Immunogen: Full length native protein (purified) (Human). Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Microlite 1+ 1x12 Strip assembled, flat bottom; the ideal vessel for low signal luminescent reactions, offering medium binding with enhanced dynamic range, extra high reflectivity and minimal cross t...
... pressurized syringe holder for any researcher who needs: ... Microinjecting Fine microliter delivery Small ... any new or existing perfusion rig - from ... to house air or a compressor (30 to ...
Biology Products: